Clinical analysis of oral moxifloxacin in the treatment of outpatients with community-acquired pneumonia
Abstract
Objective To observe the efficacy and safety of oral moxifloxacin in the treatment of outpatients with community-acquired pneumonia. Methods Fifty-six cases of community-acquired pneumonia patients used oral moxifloxacin. Meanwhile, the other 60 cases of patients used intravenous levofloxacin. Clinic index,bacterium clearance,curative effect and safety were observed. Results The clinical efficacy in the trial and control group were 94.6% and 92.6% respectively,and the bacterial eradication rates were 90.0% and 90.2%, The adverse drug reaction rates were evaluated in all patients, showing the rates were 7.1% and 18.5%. Conclusions Oral moxifloxacin is effective,simple and safe in the treatment of outpatients with community-acquired pneumonia.
Key words:
Community-acquired pneumonia; Moxifloxacin; Levofloxacin
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.